GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Medicenna Therapeutics MDNA.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

0.45

+2.27%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Medicenna Therapeutics — daily TSX:MDNA Delayed
Market value
C$34.5m
Last close × shares
Volume
41.3k
Shares, 9 Nov 2026

About Medicenna Therapeutics

Its shares trade on Toronto Stock Exchange under the ticker MDNA.TO. It has been listed since 13 July 2015.

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company is headquartered in Toronto, Ontario. The company went IPO on 2015-07-13. The firm is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The firm focuses on commercialization EC and Superkines for the treatment of cancer. The firm's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The firm's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.

Figures and description from our data supplier, not checked against the company's own report.

More about Medicenna Therapeutics →

Latest on Medicenna Therapeutics

Our reporting

We have not reported on Medicenna Therapeutics yet.

Next results

12 Nov 2026

Due on 12 Nov 2026. Analysts expect earnings of -0.04 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Medicenna Therapeutics's ticker?

Medicenna Therapeutics trades as MDNA.TO on Toronto Stock Exchange, under ISIN CA58490H1073.

What was Medicenna Therapeutics's last closing price?

0.45 on 9 Nov 2026. The figure is in CAD and is never converted.

When does Medicenna Therapeutics next report results?

Results are expected on 12 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.